Orchestra BioMed Holdings, Inc. OBIO
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 24.17% | 15.31% | 17.61% | 13.64% | -30.19% |
| Total Depreciation and Amortization | 12.16% | 7.72% | 5.36% | 6.17% | 11.15% |
| Total Amortization of Deferred Charges | 41.76% | 104.88% | 202.60% | 593.55% | 5,966.67% |
| Total Other Non-Cash Items | -40.53% | 7.16% | 6.93% | 24.57% | 54.99% |
| Change in Net Operating Assets | -2,883.52% | -404.63% | -16,612.66% | -1,255.82% | 13.28% |
| Cash from Operations | -5.11% | 1.79% | -0.84% | 3.15% | -25.50% |
| Capital Expenditure | -54.63% | -144.06% | -42.75% | -69.20% | -212.22% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 24.95% | -352.97% | -236.94% | -289.21% | -123.55% |
| Cash from Investing | 24.99% | -364.87% | -246.45% | -305.83% | -125.97% |
| Total Debt Issued | 0.00% | 266.67% | 33.33% | 33.33% | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -76.77% | 329.68% | 324.84% | 288.96% | 276.68% |
| Repurchase of Common Stock | 23.75% | 0.88% | -62.11% | -182.18% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 41.73% | -276.53% | -276.53% | -276.53% | -- |
| Cash from Financing | -34.40% | 357.68% | 226.28% | 202.81% | 1,879.24% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -186.86% | 134.71% | 301.35% | 249.78% | 151.37% |